FDA Approves First mRNA Flu Shot
The FDA has approved the first mRNA flu vaccine in the United States after a clinical trial found it was about 27% more effective than a standard flu shot. Manufactured by Moderna and marketed as mFlusiva, the vaccine is expected to be available this fall for adults ages 50 to 64 and those 65 and older, though approval for the older group is conditional on Moderna conducting an additional clinical trial, N … ⌘ Read more